Valinomycin: Physiology and What Research Reports

What Valinomycin Is

Valinomycin is a cyclic dodecadepsipeptide: a twelve-residue ring built from alternating amino acids and hydroxy acids, closed by both amide and ester bonds. Because the ring contains ester linkages it is classed as a macrolactone rather than a conventional peptide, and researchers described it as a nonribosomal macrolactone peptide assembled by a multi-enzyme nonribosomal peptide synthetase system rather than by ribosomes (PMID 32224263). Its outer surface is hydrophobic and its interior is lined with carbonyl oxygens, which is the structural basis for the behaviour it is best known for — selective potassium transport.

Valinomycin is not an endogenous human molecule. It is not produced in human tissue, has no known human receptor, and does not appear in the body unless introduced experimentally. Readers who encounter the term in peptide contexts usually meet it as a laboratory tool or as an example of microbial peptide chemistry, not as a signalling peptide like the hormone-derived sequences that dominate peptide literature.

Where It Is Produced

The compound is a secondary metabolite of soil and marine-associated Streptomyces species. Researchers reported efficient production of valinomycin by the soil bacterium Streptomyces sp. ZJUT-IFE-354 (PMID 34926115), and a follow-up study optimised the fermentation medium and culture conditions with the stated aim of enhancing valinomycin output from the same strain (PMID 35323097). A separate isolate from a sea cucumber-associated bacterium, Streptomyces sp. SV 21, was also reported as a source of valinomycin and structurally related analogues (PMID 33540548).

Beyond fermentation, the biosynthetic pathway has been rebuilt outside its native host. One study reported reconstituted biosynthesis of the nonribosomal macrolactone antibiotic valinomycin in Escherichia coli (PMID 24350980), and a later study reported total in vitro biosynthesis using purified enzymatic components, i.e. assembly in a cell-free system (PMID 32224263). Together these reports make valinomycin a recurring model system for how large nonribosomal depsipeptides are made.

What It Does at the Membrane

Valinomycin functions as a mobile carrier ionophore. The macrocycle encloses a cation, shields it with a lipophilic exterior, and shuttles it across the low-dielectric interior of a lipid membrane. Researchers measured single-molecule electrical currents associated with valinomycin transport of K+, directly linking individual carrier events to measurable charge movement (PMID 37068060). In model membranes, a study of valinomycin doping reported changes in the electrical and structural properties of planar lipid bilayers supported on polyelectrolyte multilayers (PMID 33227594), which is the standard way the ionophore's conductance contribution is characterised.

Selectivity comes from how well the ring's binding cavity matches a given ion's size and coordination preferences. Cryogenic ion trap infrared spectroscopy reported cation-responsive cavity expansion, meaning the macrocycle adjusts its internal dimensions depending on which cation it holds (PMID 36519454). A related gas-phase study described multipodal coordination and mobility of molecular cations inside the valinomycin macrocycle, showing that bound species are not necessarily locked in a single rigid pose (PMID 32840521). Computational work extended this to engineered variants: researchers carried out a theoretical investigation of hydroxylated analogues of valinomycin as potassium transporters (PMID 37523834).

How Valinomycin Is Measured and Studied

Solid-state behaviour matters for analytical reproducibility, and researchers reported that valinomycin exists in more than one polymorphic form, characterised by combining NMR measurements with crystallographic computation (PMID 32664570). Different conformers of the same macrocycle can differ in how they present their binding cavity, which is one reason structural studies recur across the valinomycin literature.

Reported Biological Activity

Because it moves potassium down its electrochemical gradient, valinomycin collapses membrane potential in cells and organelles that depend on a potassium gradient — the mechanistic reason it shows antimicrobial behaviour in culture. A study of valinomycin and its analogues from Streptomyces sp. SV 21 reported anti-infective and antiviral activity in laboratory assays (PMID 33540548). That finding is an in vitro observation; the cited work did not evaluate human treatment.

Cellular Stress Signals: What Studies Report

Valinomycin is routinely used as a stressor precisely because it disrupts ion homeostasis. One cell study reported that quercetin mitigated valinomycin-induced cellular stress, and the authors attributed the effect to stress-induced metabolism and cellular uptake of quercetin rather than to a direct chemical interaction (PMID 26865218). None of the verified studies on this page reported human dosing, human safety data, or clinical adverse-event rates, and none should be read as describing therapeutic use. This page is for educational purposes only and is not medical advice; consult a licensed physician for any health question.

Why It Matters to Peptide Readers

• It defines the depsipeptide class. Valinomycin is the textbook example of an ester-containing peptide ring made by nonribosomal enzymes rather than ribosomes (PMID 32224263).
• It separates "peptide" from "signalling peptide." Its activity comes from ion chemistry, not receptor binding, as the transport studies show (PMID 37068060).
• It is a reference tool. Membrane-potential experiments and potassium-selective sensing both rely on its selectivity, characterised in bilayer work (PMID 33227594).
• It is a synthetic-biology benchmark. Its pathway was reconstituted in E. coli, making it a test case for heterologous peptide production (PMID 24350980).

Limits of the Current Literature

The verified body of work here is dominated by chemistry, biophysics, microbial production and cell-culture pharmacology. There are no human trials among these papers, no reported human pharmacokinetics, and no dosing information to summarise. Analogue design remains mostly computational: the hydroxylated variants were assessed theoretically as potassium transporters rather than tested in animals (PMID 37523834). Readers encountering valinomycin in a protocol description are almost always seeing a laboratory reagent used to manipulate potassium gradients, not a candidate therapeutic.

References

• Total in vitro biosynthesis of the nonribosomal macrolactone peptide valinomycin (Metabolic Engineering, 2020)
• Reconstituted biosynthesis of the nonribosomal macrolactone antibiotic valinomycin in Escherichia coli (ACS Synthetic Biology, 2014)
• Efficient production of valinomycin by the soil bacterium, Streptomyces sp. ZJUT-IFE-354 (3 Biotech, 2022)
• Optimization of fermentation medium and conditions for enhancing valinomycin production by Streptomyces sp. ZJUT-IFE-354 (Preparative Biochemistry & Biotechnology, 2023)
• Single-Molecule Electrical Currents Associated with Valinomycin Transport of K+ (ACS Nano, 2023)
• Effects of valinomycin doping on the electrical and structural properties of planar lipid bilayers supported on polyelectrolyte multilayers (Bioelectrochemistry, 2021)
• Cation-responsive cavity expansion of valinomycin revealed by cryogenic ion trap infrared spectroscopy (PCCP, 2023)
• Multipodal coordination and mobility of molecular cations inside the macrocycle valinomycin (PCCP, 2020)
• Polymorphic Forms of Valinomycin Investigated by NMR Crystallography (International Journal of Molecular Sciences, 2020)
• Theoretical investigation of hydroxylated analogues of valinomycin as potassium transporter (Computational Biology and Chemistry, 2023)
• Anti-Infective and Antiviral Activity of Valinomycin and Its Analogues from a Sea Cucumber-Associated Bacterium, Streptomyces sp. SV 21 (Marine Drugs, 2021)
• Quercetin mitigates valinomycin-induced cellular stress via stress-induced metabolism and cell uptake (Molecular Nutrition & Food Research, 2016)